N. Thatcher

发表

G1 control gene status is frequently altered in resectable non‐small cell lung cancer

X. Liu, J. Heighway, D. Betticher, 1997, International journal of cancer.

Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non–small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study

Michael Thomas, N. Thatcher, J. Goldschmidt, 2019, Clinical Cancer Research.

Therapeutic vaccines for cancer: an overview of clinical trials

I. Melero, H. Mellstedt, N. Thatcher, 2014, Nature Reviews Clinical Oncology.

Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study.

H. Hansen, N. Thatcher, H. Anderson, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The pharmacokinetics of ifosfamide given as short and long intravenous infusions in cancer patients.

N. Thatcher, L. Lewis, P. Harper, 1991, British journal of clinical pharmacology.

Comparative pharmacokinetics and alkylating activity of fractionated intravenous and oral ifosfamide in patients with bronchogenic carcinoma.

P. Wilkinson, N. Thatcher, M. Lind, 1989, Cancer research.

Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non–small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study

Michael Thomas, N. Thatcher, J. Goldschmidt, 2019, Clinical Cancer Research.

Expression of p16INK4a/p16α and p19ARF/p16β is frequently altered in non-small cell lung cancer and correlates with p53 overexpression

M. Tschan, M. Fey, M. Borner, 1998, Oncogene.

Management of small-cell lung cancer.

C. Faivre-Finn, P. Lorigan, N. Thatcher, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma.

M. Ranson, A. Arance, P. Lorigan, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Second-Line Treatment of Advanced Non-small Cell Lung Cancer

N. Hanna, C. Gridelli, J. Heymach, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The expanding role of systemic treatment in NSCLC

R. Stahel, E. Felip, T. Chevalier, 2006 .

Escalating drug delivery in cancer chemotherapy: a review of concepts and practice--Part 1.

D. Dodwell, N. Thatcher, H. Gurney, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.

M. Gore, P. Lorigan, N. Thatcher, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant interferon in melanoma – a resurrection?

N. Thatcher, M. Middleton, 2001, British Journal of Cancer.

Domiciliary chemotherapy with gemcitabine is safe and acceptable to advanced non-small-cell lung cancer patients: results of a feasibility study

N Thatcher, M. Peake, N. Thatcher, 2003, British Journal of Cancer.

Symptomatic benefit from gemcitabine and other chemotherapy in advanced non-small cell lung cancer: changes in performance status and tumour-related symptoms.

M. Ranson, D. Betticher, N. Thatcher, 1995 .

Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer – a randomized trial with quality of life as the primary outcome

R. Stephens, J. Carmichael, N. Thatcher, 2000, British Journal of Cancer.

Chemotherapy in the management of invasive bladder cancer

N. Thatcher, H. Bush, R. Barnard, 1979, Cancer Chemotherapy and Pharmacology.

Randomized P hase I I S tudy o f T emozolomide G iven E very 8 Hours o r D aily W ith E ither I nterferon A lfa-2b o r T halidomide in M etastatic M alignant M elanoma

M. Ranson, A. Arance, P. Lorigan, 2003 .

Randomized P hase I II S tudy o f T emozolomide V ersus Dacarbazine i n t he T reatment o f P atients W ith A dvanced Metastatic M alignant M elanoma

D. Schadendorf, M. Gore, N. Aaronson, 2000 .

Four-hourly scheduling of temozolomide improves tumour growth delay but not therapeutic index in A375M melanoma xenografts

G. Margison, N. Thatcher, M. Middleton, 2000, Cancer Chemotherapy and Pharmacology.

Inactivation of O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide.

D. Crowther, G. Margison, N. Thatcher, 1994, British Journal of Cancer.

Genetic predisposition to human lung cancer.

P. Hasleton, J. Heighway, N. Thatcher, 1986, British Journal of Cancer.

Expression of p16INK4a/p16alpha and p19ARF/p16beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpression.

M. Tschan, M. Fey, M. Borner, 1998, Oncogene.

Statistical controversies in clinical research: futility analyses in oncology–lessons on potential pitfalls from a randomized controlled trial

N. Hanna, R. Kaiser, E. Lesaffre, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) given as a twice weekly schedule to previously untreated patients with non-small cell lung cancer.

P. Dombernowsky, N. Thatcher, H. Anderson, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Management of unresectable stage III non-small-cell lung cancer with combined-modality therapy: a review of the current literature and recommendations for treatment.

C. Faivre-Finn, F. Blackhall, N. Thatcher, 2008, Clinical lung cancer.

Randomised phase II study of cisplatin-etoposide versus infusional carboplatin in advanced non-small-cell lung cancer and mesothelioma.

G. Jayson, M. Ranson, N. Thatcher, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Chemotherapy in non-small cell lung cancer.

M. Ranson, N. Thatcher, S. Lee, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment evaluation of combined modality therapy: 'what can we obtain today from phase II trials?'.

N. Thatcher, Nick Thatcher, 1994, Lung cancer.

Haemopoietic cell kinetics in humans treated with rGM‐CSF

J. Chang, D. Crowther, T. Dexter, 1992, International journal of cancer.

Update on targeted therapies for small cell carcinoma of the lung

R. Griffiths, P. Lorigan, F. Blackhall, 2008, Targeted Oncology.

Erlotinib in non-small cell lung cancer: a review

S. Rehman, F. Blackhall, N. Thatcher, 2005, Expert opinion on pharmacotherapy.

The feasibility of using glycosylated recombinant human granulocyte colonystimulating factor (G-CSF) to increase the planned dose intensity of doxorubicin; cyclophosphamide and etoposide (ACE) in the treatment of small cell lung cancer

D. Girling, D. Machin, N. Bleehen, 1995 .

Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non–Small Cell Lung Cancer: The AvaALL Randomized Clinical Trial

C. Gridelli, K. Syrigos, Y. Ohe, 2018, JAMA oncology.

Management of elderly patients with lung cancer

M. Ranson, N. Thatcher, S. White, 2000, Current oncology reports.

Volunteers or victims: patients' views of randomised cancer clinical trials.

A. Bowling, M. Slevin, N. Thatcher, 1995, British Journal of Cancer.

Identical chemotherapy schedules given on and off trial protocol in small cell lung cancer response and survival results

A. Arance, N. Thatcher, L. Ashcroft, 2002, British Journal of Cancer.

Conducting clinical research in the new NHS: the model of cancer

N. Thatcher, M. Richards, J. Mossman, 1994, BMJ.

Treatment of malignant pleural effusions with intrapleural Corynebacterium parvum or tetracycline.

T. B. Stretton, N. Thatcher, D. Honeybourne, 1985, European journal of respiratory diseases.

A randomised controlled trial of pre-operative chemotherapy followed, if feasible, by resection versus radiotherapy in patients with inoperable stage T3, N1, M0 or T1-3, N2, M0 non-small cell lung cancer.

D. Girling, R. Stephens, N. Thatcher, 2005, Lung cancer.

The place of targeted therapy in the patient management of non-small cell lung cancer.

N. Thatcher, 2007, Lung cancer.

Changes in body composition in men and women with advanced nonsmall cell lung cancer (NSCLC) undergoing chemotherapy.

N. Thatcher, I. Campbell, M. Harvie, 2003, Journal of human nutrition and dietetics : the official journal of the British Dietetic Association.

Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma

M. Ranson, K. O'Byrne, M. Clemons, 2003, Cancer.

ACTH precursors characterize the ectopic ACTH syndrome

D. London, N. Thatcher, A. White, 1994, Clinical endocrinology.

Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis.

V. Torri, A. Rossi, D. Galetta, 2011, Lung cancer.

Role of colony stimulating factors (CSFs) in solid tumours: results of an expert panel.

S. Barni, C. Gridelli, F. de Marinis, 2007, Critical reviews in oncology/hematology.

1st ESMO Consensus Conference in lung cancer; Lugano 2010: small-cell lung cancer.

P. Postmus, R. Stahel, E. Felip, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Maintenance and Consolidation Therapy in Patients with Unresectable Stage III/IV Non-Small Cell Lung Cancer

J. Heighway, N. Thatcher, 2010, The oncologist.

The Influence of Sex in Non-Small Cell Lung Cancer

F. Blackhall, N. Thatcher, P. Wheatley‐Price, 2009, Oncology Research and Treatment.

Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer.

T. Ciuleanu, N. Thatcher, M. O'Brien, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Survival improvement in thoracic cancer: progress from the last decade and beyond.

N. Thatcher, C. Manegold, 2007, Lung cancer.

Randomized phase II study of cyclophosphamide, doxorubicin, and vincristine compared with single‐agent carboplatin in patients with poor prognosis small cell lung carcinoma

A. Arance, P. Lorigan, N. Thatcher, 2001, Cancer.

Omitting elective nodal irradiation during thoracic irradiation in limited-stage small cell lung cancer--evidence from a phase II trial.

C. Faivre-Finn, P. Lorigan, F. Blackhall, 2012, Lung cancer.

Standard versus Dose-Intensified Chemotherapy with Sequential Reinfusion of Hematopoietic Progenitor Cells in Small Cell Lung Cancer Patients with Favorable Prognosis

N. Thatcher, L. Pilz, P. Drings, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Ifosfamide, carboplatin, and etoposide with midcycle vincristine versus standard chemotherapy in patients with small-cell lung cancer and good performance status: clinical and quality-of-life results of the British Medical Research Council multicenter randomized LU21 trial.

D. Girling, R. Stephens, P. Clark, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer.

P. Lorigan, P. Woll, N. Thatcher, 2005, Journal of the National Cancer Institute.

Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer group.

C. Faivre-Finn, P. Lorigan, F. Blackhall, 2011, Lung cancer.

A phase II study of ifosfamide and a2b-interferon in advanced non-small-cell lung cancer

N. Thatcher, H. Gurney, M. Lind, 2004, Cancer Chemotherapy and Pharmacology.

Increasing and planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) by adding recombinant human methionyl granulocyte colony-stimulating factor (G-CSF; filgrastim) in the treatment of small cell lung cancer (SCLC). Medical Research Council Lung Cancer Working Party.

D. Machin, D. Girling, R. Stephens, 1995, Clinical oncology (Royal College of Radiologists (Great Britain)).

ERCC1 mRNA Expression Is Not Associated with Response and Survival after Platinum-Based Chemotherapy Regimens in Advanced Non-Small Cell Lung Cancer

R. Booton, T. Ward, Julie Morris, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Totality of evidence in the development of ABP 215, an approved bevacizumab biosimilar.

Michael Thomas, Y. Ohe, N. Thatcher, 2019, Immunotherapy.

Small Cell Lung Cancer (SCLC); any progress?

C. Faivre-Finn, P. Lorigan, F. Blackhall, 2007 .

A Phase I Study of Vandetanib in Combination with Vinorelbine/Cisplatin or Gemcitabine/Cisplatin as First-Line Treatment for Advanced Non-small Cell Lung Cancer

M. Nicolson, F. Blackhall, P. Schmid, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study.

N. Pavlakis, Yi-long Wu, L. Crinò, 2010, The Lancet. Oncology.

Treatment of small cell lung carcinoma in association with cryptogenic fibrosing alveolitis

J. Winstanley, N. Thatcher, J. Lipton, 1982, Postgraduate medical journal.

Perspectives on novel therapies for bronchial carcinoma

F. Blackhall, N. Thatcher, S. Danson, 2005, Expert opinion on pharmacotherapy.

A phase II study of erlotinib as first-line treatment of advanced non-small cell lung cancer.

G. Giaccone, E. Smit, J. Soria, 2005 .

Integrating new targeted agents into the treatment of non-small-cell lung cancer.

N. Thatcher, 2006, Lung cancer.

Pr4 ISEL: A Phase III survival study comparing gefitinib (IRESSA) plus best supportive care (BSC) with placebo plus BSC, in patients with advanced non-small-cell lung cancer (NSCLC) who had received one or two prior chemotherapy regimens

N. Thatcher, P. Parikh, A. Chang, 2005 .

Expression of epidermal growth factor receptor (EGF-R) in non-small cell lung cancer. Use of archival tissue and correlation of EGF-R with histology, tumour size, node status and survival.

P. Hasleton, D. Barnes, N. Thatcher, 1989, British Journal of Cancer.

Pemetrexed in small-cell lung cancer: background and review of the ongoing GALES pivotal trial

P. Lorigan, N. Thatcher, R. Ferraldeschi, 2007, Expert review of anticancer therapy.

Where next for gefi tinib in patients with lung cancer

M. Ranson, F. Blackhall, N. Thatcher, 2006 .

9003 Response and progression-free survival in 1006 patients with known EGFR mutation status in phase III randomized trials of gefitinib in individuals with non-small cell lung cancer

Edward S. Kim, M. Kris, T. Mok, 2009 .

Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer.

F. Hirsch, C. Watkins, P. Bunn, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gefitinib or docetaxel in advanced non-small-cell lung cancer

N. Thatcher, M. Cullen, 2008, The Lancet.

EGFR Gene Copy Number by FISH May Predict Outcome of Necitumumab in Squamous Lung Carcinomas: Analysis from the SQUIRE Study

M. Socinski, R. Kurek, F. Hirsch, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

Kevin Carroll, Nick Thatcher, Alex Chang, 2005, The Lancet.

The ISEL and BR21 trials – Outcomes similar or different?

N. Thatcher, 2006 .

Expression of epidermal growth factor receptor (EGF-R) in human lung tumours.

P. Hasleton, D. Barnes, W. Gullick, 1986, British Journal of Cancer.

Constitutional frequencies of c-Ha-ras alleles in patients with different types of lung cancer.

M. Santibanez-Koref, J. Heighway, G. White, 1990, British Journal of Cancer.

Epidermal growth factor receptor (EGFR) immunohistochemistry: Comparison of antibodies (Abs) and cut points to predict benefit from gefitinib in a phase III placebo-controlled study in advanced non-small cell lung cancer (NSCLC)

F. Hirsch, C. Watkins, P. Bunn, 2007 .

Abnormal expression of CCND1 and RB1 in resection margin epithelia of lung cancer patients.

P. Hasleton, J. Heighway, D. Betticher, 1997, British Journal of Cancer.

O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma.

G. Rustin, N. Bleehen, E. Newlands, 1998, British Journal of Cancer.

A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) chemotherapy plus necitumumab (IMC-11F8/LY3012211) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC).

C. Schumann, M. Socinski, F. Hirsch, 2014 .

Second IASLC Workshop on combined Radiotherapy and Chemotherapy Modalities in Lung Cancer. Treatment evaluation.

M. Parmar, R. Arriagada, J. Pignon, 1994, Lung Cancer.

Concise manual of hematology and oncology

M. Andreeff, R. Mertelsmann, N. Thatcher, 2008 .

Human lymphocyte traffic assessed by indium-111 oxine labelling: clinical observations.

D. Crowther, N. Thatcher, J. Wagstaff, 1981, Clinical and experimental immunology.

Multicyclic, dose-intensive chemotherapy supported by sequential reinfusion of hematopoietic progenitors in whole blood.

T. Dexter, P. Woll, N. Thatcher, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution

P. Wilkinson, N. Thatcher, M. Lind, 2004, Cancer Chemotherapy and Pharmacology.

Treatment of non-small-cell lung cancer: a perspective on the recent advances and the experience with gefitinib

M. Tsuboi, N. Thatcher, A. Onn, 2004, British Journal of Cancer.

Dose intensity in cancer chemotherapy.

D. Dodwell, N. Thatcher, H. Gurney, 1990, British Journal of Cancer.

Gemcitabine: once‐weekly schedule active and better tolerated than twice‐weekly schedule

N. Thatcher, C. Martín, H. Anderson, 1996, Anti-cancer drugs.

Use of G-CSF during concurrent chemotherapy and thoracic radiotherapy in patients with limited-stage small-cell lung cancer safety data from a phase II trial.

C. Faivre-Finn, P. Lorigan, F. Blackhall, 2011, Lung cancer.

Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer

C. Faivre-Finn, P. Lorigan, F. Blackhall, 2008, British Journal of Cancer.

11-WEEK COURSE OF SEQUENTIAL METHOTREXATE, THORACIC IRRADIATION, AND MODERATE-DOSE CYCLOPHOSPHAMIDE FOR "LIMITED"-STAGE SMALL-CELL BRONCHOGENIC CARCINOMA A Study from the Manchester Lung Tumour Group

P. Wilkinson, D. Crowther, N. Thatcher, 1982, The Lancet.

A retrospective study of thirty-two patients with small-cell bronchogenic carcinoma and inappropriate secretion of antidiuretic hormone.

N. Thatcher, J. Lockton, 1986, Clinical radiology.

Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data

P. Hasleton, N. Thatcher, J. King, 2006, Histopathology.

A method for following human lymphocyte traffic using indium-111 oxine labelling.

D. Crowther, N. Thatcher, J. Wagstaff, 1981, Clinical and experimental immunology.

Second Heidelberg Thoracic Oncology Symposium on the Diagnosis and Treatment of Pleural Mesothelioma--introduction.

N. Thatcher, 2004, Lung cancer.

The effect of ifosfamide and its metabolites on intracellular glutathione levels in vitro and in vivo.

D. Crowther, M. Lind, N. Thatcher, 1989, Biochemical pharmacology.

24 Phase III study of gemcitabine (Gemzar®) versus best supportive care (BSC) in advanced non-small cell lung cancer (NSCLC)

J. Carmichael, M. Nicolson, N. Thatcher, 1997 .

[Breast cancer in the early stage].

R. J. Jones, M. Espié, G. Giaccone, 2012, Gan no rinsho. Japan journal of cancer clinics.

Advanced recurrent squamous cell carcinoma of the head and neck. Results of a chemotherapeutic regimen with adriamycin, bleomycin, 5‐fluorouracil, methotrexate, and vitamin A

D. Crowther, N. Thatcher, G. Blackledge, 1980, Cancer.

Dosage and cycle effects of dacarbazine (DTIC) and fotemustine on O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells.

G. Margison, N. Thatcher, S. Lee, 1993, British Journal of Cancer.

A phase II trial with RFS2000 (rubitecan) in patients with advanced non-small cell lung cancer.

M. Ranson, P. Lorigan, N. Thatcher, 2005, European journal of cancer.

Phase II study of oral topotecan in advanced non-small cell lung cancer.

M. Ranson, N. Thatcher, B. Carrington, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Recombinant interleukin-2 (rIL-2) with flavone acetic acid (FAA) in advanced malignant melanoma: immunological studies.

A. Ghosh, N. Thatcher, M. Mellor, 1990, British Journal of Cancer.

Lack of correlation between peripheral blood lymphokine‐activated killer (lak) cell function and clinical response in patients with advanced malignant melanoma receiving recombinant interleukin 2

A. Ghosh, N. Thatcher, H. Dazzi, 1989, International journal of cancer.

Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer.

D. Crowther, T. Dexter, N. Thatcher, 1987, British Journal of Cancer.

Filgrastim with dose intensified CDE chemotherapy in small cell lung cancer

P. Clark, N. Thatcher, C. Manegold, 1993 .

Interleukin 2: Clinical Aspects

N. Thatcher, 1990 .

Immunomodulation during prolonged treatment with combined interleukin-2 and interferon-alpha in patients with advanced malignancy.

P. Stern, A. Ghosh, N. Thatcher, 1993, British Journal of Cancer.

Standard of Care for Cancer-Related Anemia: Improving Hemoglobin Levels and Quality of Life

P. Wilkinson, P. Gascón, N. Thatcher, 2005, Oncology.

A clinicopathological study of the paraneoplastic neuromuscular syndromes associated with lung cancer.

N. Thatcher, S. Gomm, W. Cumming, 1990, The Quarterly journal of medicine.

Tecemotide ( L-BLP 25 ) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer ( START ) : a randomised , double-blind , phase 3 trial

M. Socinski, F. Shepherd, R. Ramlau, 2013 .

Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.

M. Socinski, F. Shepherd, R. Ramlau, 2014, The Lancet. Oncology.

Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses.

M. Socinski, F. Shepherd, A. Szczesna, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Combination treatment with Interleukin-2 and chemotherapeutic agents

N. Thatcher, A. Rohr, 1993 .

Current trends in prophylactic cranial irradiation (PCI) for extensive-disease small cell lung cancer (EDSCLC): Results of a UK survey

C. Faivre-Finn, P. Lorigan, F. Blackhall, 2008 .

Clinical applications of interleukin-2.

N. Thatcher, A. von Rohr, 1992, Progress in growth factor research.

Dose-finding study of fixed dose gemcitabine and escalating doses of ifosfamide given on days 1 and 8 in patients with advanced non-small cell lung cancer.

P. Lorigan, F. Blackhall, N. Thatcher, 2006, Lung cancer.

Small-cell lung cancer

P. Woll, T. le Chevalier, N. Thatcher, 2018 .

Use of hematopoietic progenitors in whole blood to support dose-dense chemotherapy: a randomized phase II trial in small-cell lung cancer patients.

P. Woll, N. Thatcher, R. Pettengell, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Randomized Trial. Medical Research Council Lung Cancer

D. Girling, R. Stephens, N. Thatcher, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer.

P. Woll, N. Thatcher, V. Cour-Chabernaud, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dose intensity in small cell lung cancer.

P. Woll, N. Thatcher, M. Middleton, 1998, Seminars in oncology.

Randomised phase II study of standard versus dose-intensive ICE chemotherapy with reinfusion of haemopoietic progenitors in whole blood in small cell lung cancer (SCLC).

P. Woll, N. Thatcher, S. Lee, 1996 .

High dose combination chemotherapy with ifosfamide, cyclophosphamide or cisplatin, mitomycin C and mustine with autologous bone marrow support in advanced non-small cell lung cancer. A phase I/II study.

N. Thatcher, J. Chang, S. Gomm, 1991, British Journal of Cancer.

In vitro and in vivo analysis of the effects of recombinant human granulocyte colony-stimulating factor in patients.

D. Crowther, T. Dexter, N. Thatcher, 1988, British Journal of Cancer.

Expert consensus on the management of erlotinib-associated cutaneous toxicity in the u.k.

M. Nicolson, N. Thatcher, J. McPhelim, 2009, The oncologist.

Carboplatin in small cell lung cancer.

N. Thatcher, M. Lind, 1990, Seminars in oncology.

Prevalence of the rhesus‐negative phenotype in caucasian patients with small‐cell lung cancer (SCLC)

M. Castiglione, M. Fey, M. Lind, 1992, International journal of cancer.

‘Dos and don’ts’ in the management of hyponatremia

A. Peri, N. Thatcher, S. Aylwin, 2015, Current medical research and opinion.

The diagnosis and management of inpatient hyponatraemia and SIADH

R. Murray, N. Thatcher, I. Cranston, 2015, European journal of clinical investigation.

Viridans streptococcal bacteraemia in patients with haematological and solid malignancies.

A. Howell, D. Crowther, N. Thatcher, 1991, European journal of cancer.

A phase I study of recombinant human interleukin-4 administered by the intravenous and subcutaneous route in patients with advanced cancer: immunological studies.

P. Stern, D. Crowther, A. Ghosh, 1993, European cytokine network.

Ifosfamide, etoposide, and thoracic irradiation therapy in 163 patients with unresectable small cell lung cancer

P. Barber, N. Thatcher, T. Cerny, 1987, Cancer.

Three months' treatment with cyclophosphamide, VP‐16‐213 followed by methotrexate and thoracic radiotherapy for small cell lung cancer

R. James, P. Barber, N. Thatcher, 1985, Cancer.

Intermittent high‐dose cyclophosphamide with and without prednisolone. A study of the relationships between toxicity, response and survival in metastatic lung cancer

D. Crowther, N. Thatcher, J. Wagstaff, 1982, Cancer.

Preliminary experience with quality of life evaluation in patients with lung cancer.

N. Thatcher, Penny Hopwood, 1990, Oncology.

Therapy for small cell lung cancer using carboplatin, ifosfamide, etoposide (without dose reduction), mid-cycle vincristine with thoracic and cranial irradiation.

P. Lorigan, N. Thatcher, J. Prendiville, 1994, European journal of cancer.

Ifosfamide/carboplatin/etoposide (ICE) regimen in small cell lung cancer

N. Thatcher, 1993 .

Phase II study with mitomycin, ifosfamide and carboplatin in inoperable non-small cell lung cancer.

N. Thatcher, H. Anderson, A. von Rohr, 1991, European journal of cancer.

Double alkylating agent therapy with ifosfamide and cyclophosphamide for advanced non‐small cell lung cancer. From the Manchester Lung Tumour Group

J. Barclay, N. Thatcher, D. Smith, 1988, Cancer.

The effect of age on the pharmacokinetics of ifosfamide.

P. Wilkinson, N. Thatcher, M. Lind, 1990, British journal of clinical pharmacology.

In vivo depletion of O6-alkylguanine-DNA-alkyltransferase in lymphocytes and melanoma of patients treated with CB 10-277, a new DTIC analogue

D. Crowther, G. Margison, N. Thatcher, 2004, Cancer Chemotherapy and Pharmacology.

New perspectives in lung cancer. 4. Haematopoietic growth factors and lung cancer treatment.

N. Thatcher, Nick Thatcher, 1992, Thorax.

Lymphohaematopoietic Growth Factor Use in Lung Cancer Patients

N. Thatcher, 1992 .

Infection risk in patients with small cell lung cancer receiving intensive chemotherapy and recombinant human granulocyte-macrophage colony-stimulating factor

J. Radford, D. Crowther, N. Thatcher, 1992 .

Recombinant human GM-CSF in small cell lung cancer: a phase I/II study.

N. Thatcher, R. Swindell, J. Weiner, 1991, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Clinical applications of myeloid colony stimulating factors.

S. Kaye, N. Thatcher, W. Steward, 1990, Cancer treatment reviews.

Growth factor-assisted chemotherapy--the Manchester experience.

A. Howell, N. Thatcher, M. Bronchud, 1990, Ciba Foundation symposium.

Recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) given as daily short infusions--a phase I dose-toxicity study.

D. Crowther, N. Thatcher, W. Steward, 1989, British Journal of Cancer.

Recombinant human interleukin-4 (rhu IL-4) administered by the intravenous and subcutaneous routes in patients with advanced cancer--a phase I toxicity study and pharmacokinetic analysis.

P. Stern, D. Crowther, A. Ghosh, 1993, European journal of cancer.

Paclitaxel: a hope for advanced non-small cell lung cancer?

M. Ranson, N. Thatcher, 1999, Expert opinion on investigational drugs.

A retrospective review of 57 patients treated with vincristine, doxorubicin, cyclophosphamide (VAC) or VAC alternating with cisplatin and etoposide (VAC/PE)

J. Radford, N. Thatcher, L. Menasce, 1994, Cancer.

Activity of JM9 in advanced ovarian cancer: a phase I-II trial.

A. Howell, D. Crowther, V. Bramwell, 1985, Cancer treatment reports.

Tropisetron compared with a metoclopramide-based regimen in the prevention of chemotherapy-induced nausea and vomiting.

A. Howell, N. Thatcher, H. Anderson, 1994, European journal of cancer.

Three months treatment with chemotherapy and radiotherapy for small cell lung cancer.

N. Thatcher, D. Smith, R. Stout, 1985, British Journal of Cancer.

Effect of in vivo administration of interferon gamma on expression of MHC products and tumour associated antigens in patients with metastatic melanoma.

A. Ghosh, N. Thatcher, J. Wagstaff, 1989, European journal of cancer & clinical oncology.

Sequencing of single-agent (SA) docetaxel (T) and gemcitabine (G) therapy for patients (pts) with advanced non-small cell lung cancer (NSCLC): Results of three consecutive randomized trials.

C. Kortsik, N. Thatcher, L. Pilz, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Recombinant IL-2 given intra-splenically and intravenously in advanced malignant melanoma: a phase I/II study.

N. Thatcher, H. Dazzi, A. Gosh, 1989, Cancer treatment reviews.

Elevated serum alpha subunit levels in patients with cancer; a consequence of gonadotrophin secretion and age.

A. J. Chapman, N. Thatcher, S. Shalet, 1987, British Journal of Cancer.

Safety of bevacizumab-based therapy as first-line treatment of patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): MO19390 (SAiL)

N. Pavlakis, L. Crinò, N. Thatcher, 2008 .

Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients.

J. Verweij, J. von Pawel, U. Gatzemeier, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dose intensification in small cell lung cancer chemotherapy

N. Thatcher, Middleton, 1998 .

Intensive therapy for small-cell lung cancer using carboplatin alternating with cisplatin, ifosfamide, etoposide, mid-cycle vincristine, and radiotherapy.

J. Radford, M. Ranson, N. Thatcher, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Single-agent paclitaxel in advanced non-small cell lung cancer: single-center phase II study using a 3-hour administration schedule.

G. Jayson, M. Ranson, N. Thatcher, 1997, Seminars in oncology.

Blood clearance of three radioactively labelled platinum complexes: cis-dichlorodiammine platinum II, cis, trans-dichlorodihydroxy-bis-(isopropylamine) platinum IV, and cis-dichloro-bis-cyclopropylamine platinum II, in patients with malignant disease

D. Crowther, N. Thatcher, B. Fox, 2004, Cancer Chemotherapy and Pharmacology.

In vivo distribution studies of radioactively labelled platinum complexes; cis-dichlorodiammine platinum(II), cis-trans-dichlorodihydroxy-bis-(isopropylamine) platinum (IV), cis-dichloro-bis-cyclopropylamine platinum(II), and cis-diammine 1,1-cyclobutanedicarboxylate platinum(II) in patients with ma

D. Crowther, N. Thatcher, S. Owens, 2004, Cancer Chemotherapy and Pharmacology.

Upper abdominal lymphadenopathy as first presentation of relapse, identified by ultrasonography, in patients treated for small cell (oat cell) bronchogenic carcinoma.

R. James, N. Thatcher, R. Johnson, 1985, British journal of diseases of the chest.

Blood clearance of radioactively labelled cis-diammine 1,1-cyclobutane dicarboxylate platinum(II) (CBDCA) in cancer patients

D. Crowther, N. Thatcher, S. Owens, 2004, Cancer Chemotherapy and Pharmacology.

High‐dose, double alkylating agent chemotherapy with DTIC, melphalan, or ifosfamide and marrow rescue for metastatic malignant melanoma

N. Thatcher, M. Lind, G. Chadwick, 1989, Cancer.

Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanoma.

A. Woodcock, N. Thatcher, G. Margison, 1993, British Journal of Cancer.

Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer.

W. Ryder, P. Hasleton, J. Heighway, 1996, British Journal of Cancer.

No study left behind: a network meta-analysis in non-small-cell lung cancer demonstrating the importance of considering all relevant data.

Neil Hawkins, N. Thatcher, N. Hawkins, 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Cost Effectiveness of Increasing the Dose Intensity of Chemotherapy with Granulocyte Colony-Stimulating Factor in Small-Cell Lung Cancer

M. Sculpher, D. Girling, R. Stephens, 2012, PharmacoEconomics.

Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports

P. Hasleton, N. Thatcher, C. Pickering, 2006, Histopathology.

Choroidal metastases from breast carcinoma: a survey of 42 patients and the use of radiation therapy.

N. Thatcher, P. Thomas, 1975, Clinical radiology.

Vaccines for the treatment of non-small cell lung cancer: investigational approaches and clinical experience.

J. Vansteenkiste, N. Thatcher, H. Mellstedt, 2011, Lung cancer.

Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer.

M. Ranson, J. Carmichael, M. Nicolson, 2000, Journal of the National Cancer Institute.

Serum glycoprotein hormone alpha sub-unit values and survival in metastatic melanoma patients.

D. Crowther, N. Thatcher, R. Swindell, 1979, European journal of cancer.

Malignant melanoma in children and adolescents

D. Crowther, M. Palmer, N. Thatcher, 1981, Cancer.

Lymphocyte function related to survival curves in patients with metastatic melanoma treated by chemoimmunotherapy.

D. Crowther, M. Palmer, N. Thatcher, 1978, Medical and pediatric oncology.

Lymphocyte function and response to chemo-immunotherapy in patients with metastatic melanoma.

D. Crowther, M. Palmer, N. Thatcher, 1977, British Journal of Cancer.

Acceptability and tolerance of a low tyrosine and phenylalanine diet in patients with advanced cancer -- a pilot study.

A. Howell, N. Thatcher, I. Campbell, 2002, Journal of human nutrition and dietetics : the official journal of the British Dietetic Association.

Effects of repeated Corynebacterium parvum and BCG therapy on immune parameters: a weekly study of melanoma patients II. Changes in serum immunoglobulins and lymphoid cell subpopulations.

D. Crowther, N. Thatcher, R. Swindell, 1979, Clinical and experimental immunology.

Treatment of metastatic melanoma by 24‐hour DTIC infusions and hemibody irradiation

R. James, N. Thatcher, H. Anderson, 1986, Cancer.

Effects of Corynebacterium parvum and BCG therapy on immune parameters in patients with disseminated melanoma. A sequential study over 28 days. II. Changes in non-specific (NK, K and T cell) lymphocytoxicity and delayed hypersensitivity skin reactions.

D. Crowther, N. Thatcher, R. Swindell, 1979, Clinical and experimental immunology.

A phase I study of intravenous bryostatin 1 in patients with advanced cancer.

P. Stern, D. Crowther, P. Woll, 1993, British Journal of Cancer.

Lymphocyte function in the blood of patients with untreated non-Hodgkin lymphoma: influence of stage and pathology.

D. Crowther, N. Thatcher, N. Gasiunas, 1977, Medical and pediatric oncology.

Effects of intermittent 5-fluorouracil and adriamycin on various immune parameters in carcinoma patients with reference to the tumour load

D. Crowther, N. Thatcher, M. Moore, 1977, Cancer Immunology, Immunotherapy.

Clinical and in vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small-cell lung cancer.

J. Radford, N. Thatcher, W. Steward, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel.

C. Gridelli, F. de Marinis, A. Ardizzoni, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

DNA analysis by flow cytometry in malignant pleural mesothelioma: Relationship to histology and survival

N. Thatcher, H. Dazzi, R. Lawson, 1990, The Journal of pathology.

The value of tumour markers in lung cancer.

P. Hasleton, B. Keevil, N. Thatcher, 1988, British Journal of Cancer.

O6‐(4‐bromothenyl)guanine improves the therapeutic index of temozolomide against A375M melanoma xenografts

G. Margison, N. Thatcher, M. Middleton, 2000, International journal of cancer.

O6-alkylguanine-DNA alkyltransferase depletion and regeneration in human peripheral lymphocytes following dacarbazine and fotemustine.

N. Thatcher, G. Margison, S. M. Lee, 1991, Cancer research.

Immunohistological examination of the inter- and intracellular distribution of O6-alkylguanine DNA-alkyltransferase in human liver and melanoma.

P. Potter, C. Fan, H. Altermatt, 1992, British Journal of Cancer.

Effect of O6‐(4‐bromothenyl)guanine on different temozolomide schedules in a human melanoma xenograft model

G. Margison, N. Thatcher, M. Middleton, 2002, International journal of cancer.

Relationships between the formation of O6-methyldeoxyguanosine by 1-p-carboxyl-3,3-dimethylphenyltriazene in DNA and O6-alkylguanine-DNA alkyltransferase in human peripheral leukocytes.

D. Crowther, D. Cooper, G. Margison, 1994, Cancer research.

Formation and loss of O6-methyldeoxyguanosine in human leucocyte DNA following sequential DTIC and fotemustine chemotherapy.

D. Cooper, N. Thatcher, G. Margison, 1994, British Journal of Cancer.

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.

C. Schumann, M. Socinski, R. Kurek, 2015, The Lancet. Oncology.

Alternate splicing produces a novel cyclin D1 transcript.

N Thatcher, W. Ryder, J. Heighway, 1995, Oncogene.

Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer.

Edward S. Kim, C. Obasaju, M. Socinski, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment

Edward S. Kim, C. Obasaju, M. Socinski, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Molecular and Immune Biomarker Testing in Squamous‐Cell Lung Cancer: Effect of Current and Future Therapies and Technologies

Edward S. Kim, C. Obasaju, M. Socinski, 2018, Clinical lung cancer.

Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer

Edward S. Kim, C. Obasaju, M. Socinski, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinicopathologic Features of Advanced Squamous NSCLC.

Edward S. Kim, C. Obasaju, M. Socinski, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancer.

H. Groen, J. Milanowski, T. Ciuleanu, 2013, Lung cancer.

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma.

D. Schadendorf, N. Aaronson, M. Muller, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.

G. Scagliotti, R. Stahel, J. Soria, 2012, European journal of cancer.

VAC (vincristine, adriamycin, cyclophosphamide) chemotherapy for metastatic carcinoma from an unknown primary site.

D. Crowther, N. Thatcher, J. Wagstaff, 1983, European journal of cancer & clinical oncology.

Predicting the myelotoxicity of chemotherapy: the use of pretreatment O6-methylguanine-DNA methyltransferase determination in peripheral blood mononuclear cells

G. Margison, P. Lorigan, N. Thatcher, 2011, Melanoma research.

Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer

N Thatcher, M. Ranson, G. Margison, 2006, British Journal of Cancer.

Effects of Corynebacterium parvum and BCG therapy on immune parameters in patients with disseminated melanoma a sequential study over 28 days. I. Changes in blood counts, serum immunoglobulins and lymphoid cell populations.

D. Crowther, N. Thatcher, R. Swindell, 1979, Clinical and experimental immunology.

A phase I study of a 24 hour infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancer.

H. Hansen, N. Thatcher, H. Anderson, 1996, British Journal of Cancer.

Neurological and cognitive impairment in long-term survivors of small cell lung cancer.

A. Gregor, A. Cull, K. Stȩpniewska, 1994, European journal of cancer.

Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer

J. Vansteenkiste, N. Thatcher, R. Rosso, 1999, British Journal of Cancer.

Where next for gefitinib in patients with lung cancer?

M. Ranson, F. Blackhall, N. Thatcher, 2006, The Lancet. Oncology.

EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients: how do we interpret the clinical and biomarker data?

F. Cappuzzo, L. Crinò, F. Blackhall, 2008, Targeted Oncology.

The Migratory Properties of Indium‐111 Oxine Labelled Lymphocytes in Patients with Chronic Lymphocytic Leukaemia

D. Crowther, N. Thatcher, J. Wagstaff, 1981, British journal of haematology.

Thoracic radiation therapy for limited-stage small-cell lung cancer: unanswered questions.

C. Faivre-Finn, P. Lorigan, C. West, 2005, Clinical lung cancer.

Effects of diphenylhydantoin on killer cell activity and other immunological functions. A sequential study including the interaction of Corynebacterium parvum in melanoma patients.

P. Wilkinson, D. Crowther, N. Thatcher, 1982, International journal of immunopharmacology.

Lymphocyte Cytotoxicity in Melanoma Patients Undergoing Immunotherapy

D. Crowther, M. Palmer, N. Thatcher, 1979 .

START: A phase III study of L-BLP25 cancer immunotherapy for unresectable stage III non-small cell lung cancer.

M. Socinski, F. Shepherd, R. Ramlau, 2013 .

Epidermal growth factor receptor inhibition in lung cancer: status 2012.

Edward S. Kim, P. Jänne, F. Cappuzzo, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Epidermal Growth Factor Receptor Inhibition in Lung Cancer

Edward S. Kim, P. Jänne, F. Cappuzzo, 2013 .

Recombinant interleukin-2 (rIL-2) with flavone acetic acid (FAA) in advanced malignant melanoma: a phase II study.

A. Ghosh, N. Thatcher, B. Carrington, 1990, British Journal of Cancer.

Modern Management of Small-Cell Lung Cancer

C. Faivre-Finn, P. Lorigan, N. Thatcher, 2012, Drugs.

Novel Therapies for the Treatment of Small-Cell Lung Cancer

P. Lorigan, N. Thatcher, R. Board, 2012, Drugs.

Antivascular agents for non-small-cell lung cancer: current status and future directions

W. Klepetko, F. Blackhall, N. Thatcher, 2009, Expert opinion on investigational drugs.

Gefitinib for the treatment of non-small-cell lung cancer

F. Blackhall, N. Thatcher, L. Campbell, 2010, Expert opinion on pharmacotherapy.

Predicting septic complications of chemotherapy: an analysis of 382 patients treated for small cell lung cancer without dose reduction after major sepsis.

J. Radford, W. Ryder, D. Dodwell, 1992, European journal of cancer.

Chemoimmunotherapy for metastatic malignant melanoma using vincristine (NSC-67574), DTIC (NSC-45388) and Bacillus Calmette-Guerin.

D. Crowther, M. Palmer, N. Thatcher, 1981, European journal of cancer.

Xeroderma pigmentosum group D haplotype predicts for response, survival, and toxicity after platinum‐based chemotherapy in advanced nonsmall cell lung cancer

R. Booton, T. Ward, Julie Morris, 2006, Cancer.

Erlotinib for Frontline Treatment of Advanced Non–Small Cell Lung Cancer: a Phase II Study

G. Giaccone, E. Smit, P. Janne, 2006, Clinical Cancer Research.

Observation of the treatment and outcomes of patients receiving chemotherapy for advanced NSCLC in Europe (ACTION study)

F. Pimentel, B. E. van den Borne, N. Thatcher, 2010, Current medical research and opinion.

A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1).

N Thatcher, R. Booton, D. Dunlop, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Chemotherapy and quality of life in advanced NSCLC – reply

M. Nicolson, N. Thatcher, P. Hopwood, 2001, British Journal of Cancer.

Aggressive vs nonaggressive therapy for metastatic NSCLC.

N. Thatcher, H. Anderson, R. Niven, 1996, Chest.

Phase II study of exatecan mesylate (DX-8951f) as first line therapy for advanced non-small cell lung cancer.

M. Ranson, J. Braybrooke, D. Talbot, 2003, Lung cancer.

Lung cancer • 7: Management of lung cancer in elderly patients

R. Booton, M. Jones, N. Thatcher, 2003, Thorax.

Lung cancer c 7: Management of lung cancer in elderly patients

R. Booton, M. Jones, N. Thatcher, 2003 .

Improving quality of life in patients with non-small cell lung cancer: research experience with gemcitabine.

N. Thatcher, P. Hopwood, H. Anderson, 1997, European journal of cancer.

Ifosfamide and mitomycin in combination for the treatment of patients with progressive advanced non-small cell lung cancer.

D. Dodwell, N. Thatcher, H. Gurney, 1991, European journal of cancer.

Quality-of-life assessment in advanced lung cancer: considerations for evaluation in patients receiving chemotherapy.

R. Gralla, N. Thatcher, 2004, Lung cancer.

Chemotherapy in advanced nonsmall cell lung cancer: indication, intensity, and duration

R. Booton, N. Thatcher, 2002, Current opinion in oncology.

Chemotherapy for advanced non-small cell lung cancer.

N. Thatcher, 2001, Lung cancer.

Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Conclusion.

P. Bunn, N. Thatcher, 2008, The oncologist.

Targeted molecular mechanisms of epoetin alfa.

F. Hirsch, C. Langer, N. Thatcher, 2003, Lung cancer.

Recombinant interleukin-2 in metastatic renal cell carcinoma--a European multicentre phase II study.

S. Fosså, N. Thatcher, H. von der Maase, 1991, European journal of cancer.

Third CECOG consensus on the systemic treatment of non-small-cell lung cancer.

C. Gridelli, F. Hirsch, V. Georgoulias, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Consensus on medical treatment of non-small cell lung cancer.

Christina J. Herold, C. Gridelli, F. Hirsch, 2002, Lung cancer.

Gemcitabine and carboplatin in combination for the treatment of advanced, metastatic, non-small cell lung cancer

F. Blackhall, N. Thatcher, R. Califano, 2007, Expert opinion on pharmacotherapy.

Platinum-based chemotherapy with thoracic radiotherapy in stage III good performance status non-small cell lung cancer patients

C. Faivre-Finn, P. Lorigan, F. Blackhall, 2005 .

Sequential Platinum-Based Chemotherapy-Thoracic Radiotherapy in Early Stage Non–Small Cell Lung Cancer

C. Faivre-Finn, P. Lorigan, F. Blackhall, 2005, Clinical Cancer Research.

Randomized phase II study of two gemcitabine schedules for patients with impaired performance status (Karnofsky performance status

D. Smith, P. Lorigan, N. Thatcher, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemotherapy for advanced non-small cell lung cancer patients with performance status 2

F. Blackhall, N. Thatcher, J. Bhosle, 2005, Current opinion in oncology.

The role of chemotherapy (CT) and supportive care (SC) in advanced non-small cell lung cancer (NSCLC).

N. Thatcher, 2002, Lung cancer.

Gefitinib (IRESSA) in Patients of Asian Origin with Refractory Advanced Non-small Cell Lung Cancer: Subset Analysis from the ISEL Study

S. Thongprasert, C. Watkins, R. Perng, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK

M. Nicolson, N. Thatcher, C. Harwood, 2015, Drugs.

Changes in cellular immunity following nephrectomy for localized and metastatic hypernephroma.

D. Crowther, N. Thatcher, R. Barnard, 1977, European journal of cancer.

A randomized phase II trial of interleukin 2 and interleukin 2-interferon alpha in advanced renal cancer.

G. Jayson, N. Thatcher, M. Middleton, 1998, British Journal of Cancer.

Turner's syndrome with coeliac disease, thin bones and abnormal liver function tests

N. Thatcher, G. Besser, A. Stephens, 1973, Postgraduate medical journal.

Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients.

R. Dummer, M. Gore, A. Eggermont, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma.

N. Bleehen, G. Rustin, N. Bleehen, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody.

P. Hasleton, N. Thatcher, R. Swindell, 1990, British Journal of Cancer.

Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?

R. Kaiser, N. Pavlakis, Keunchil Park, 2019, Future oncology.

Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial.

G. Scagliotti, F. Shepherd, S. Novello, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Recombinant interleukin-2 (rIL-2) given intrasplenically and intravenously for advanced malignant melanoma. A phase I and II study.

A. Ghosh, N. Thatcher, H. Dazzi, 1989, British Journal of Cancer.

Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: a randomised phase II study.

M. Ranson, D. Betticher, N. Thatcher, 1995, British Journal of Cancer.

Pretreatment prognostic factors and scoring system in 407 small‐cell lung cancer patients

V. Bramwell, N. Thatcher, H. Anderson, 1987, International journal of cancer.

Awareness and understanding of cancer immunotherapy in Europe

I. Melero, H. Mellstedt, N. Thatcher, 2014, Human vaccines & immunotherapeutics.

Awareness and understanding of cancer immunotherapy in Europe.

I. Melero, H. Mellstedt, N. Thatcher, 2013 .

Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study.

M. Gore, J. Kirkwood, A. Buzaid, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma

P. Lorigan, N. Thatcher, M. Middleton, 2000, British Journal of Cancer.

Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial).

J. S. Lee, D. R. Berry, G. Giaccone, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer.

M. Krzakowski, J. Jassem, E. Tan, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Two randomised phase II trials of subcutaneous interleukin-2 and histamine dihydrochloride in patients with metastatic renal cell carcinoma

N. Thatcher, H. von der Maase, M. Middleton, 2005, British Journal of Cancer.

Melanoma: chemotherapy.

D. Betticher, N. Thatcher, S. M. Lee, 1995, British medical bulletin.

DNA analysis by flow cytometry in nonsmall cell lung cancer: relationship to epidermal growth factor receptor, histology, tumour stage and survival.

P. Hasleton, N. Thatcher, R. Swindell, 1990, Respiratory medicine.

Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer.

T. Eisen, W. Miller, S. Leyvraz, 2009, Lung cancer.

Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.

C. Schumann, M. Socinski, R. Kurek, 2015, The Lancet. Oncology.

Randomized study of Corynebacterium parvum adjuvant therapy following surgery for (Stage II) malignant melanoma

N. Thatcher, S. Banerjee, C. Orton, 1986, The British journal of surgery.

Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin.

M. Socinski, E. Smit, P. Lorigan, 2012, Lung cancer.

Corynebacterium parvum followed by chemotherapy (actinomycin D and DTIC) compared with chemotherapy alone for metastatic malignant melanoma.

N. Thatcher, J. Wagstaff, D. Smith, 1986, European journal of cancer & clinical oncology.

Venous thromboembolism with EGFR monoclonal antibody necitumumab in stage IV non-small cell lung cancer: A retrospective cohort analysis.

R. Kurek, F. Shepherd, L. Paz-Ares, 2018, Thrombosis research.

Management of the solitary metastasis.

N. Thatcher, R. McIntosh, 1990, Thorax.

A simple quantitative HPLC assay for ifosfamide in biological fluids.

P. Wilkinson, N. Thatcher, J. Margison, 1986, Biomedical chromatography : BMC.

Moderate to high dose cyclophosphamide and intercalated Corynebacterium parvum in patients with metastatic lung cancer.

D. Crowther, N. Thatcher, J. Wagstaff, 1984, British journal of diseases of the chest.

Effects of repeated Corynebacterium parvum and BCG therapy on immune parameters: a weekly sequential study of melanoma patients. I. Changes in non-specific (NK, K and T cell) lymphocytotoxicity, peripheral blood counts and delayed hypersensitivity reactions.

D. Crowther, N. Thatcher, R. Swindell, 1979, Clinical and experimental immunology.

Phase II Study of Continuous Subcutaneous Interferon-Alfa Combined with Cisplatin in Advanced Malignant Melanoma

A. Harris, S. Fosså, A. Einstein, 1992 .

Options for first- and second-line therapy in small cell lung cancer--a workshop discussion.

Mark R. Green, N. Thatcher, J. Eckardt, 2003, Lung cancer.

Inter- and intracellular heterogeneity of O6-alkylguanine-DNA alkyltransferase expression in human brain tumors: possible significance in nitrosourea therapy.

G. Margison, N. Thatcher, R. Elder, 1996, Carcinogenesis.

Therapy for poor-risk patients with small-cell lung cancer using bolus ifosfamide and oral etoposide

A. Woodcock, N. Thatcher, R. Swindell, 2008, Cancer Chemotherapy and Pharmacology.

The effect of route of administration and fractionation of dose on the metabolism of ifosfamide

H. L. Roberts, J. Idle, N. Thatcher, 2008, Cancer Chemotherapy and Pharmacology.

Bioavailability of ifosfamide in patients with bronchial carcinoma.

P. Wilkinson, N. Thatcher, J. Margison, 1986, Journal of Cancer Research and Clinical Oncology.

Ifosfamide by bolus as treatment for advanced non-small cell lung cancer

N. Thatcher, W. Steward, D. Smith, 2004, Cancer Chemotherapy and Pharmacology.

Ifosfamide, doxorubicin and etoposide in small cell lung cancer patients with poor prognosis.

M. Ranson, N. Thatcher, M. Bronchud, 1990, European journal of cancer.

Carboplatin, ifosfamide and etoposide with mid-course vincristine and thoracic radiotherapy for 'limited' stage small cell carcinoma of the bronchus.

N. Thatcher, M. Lind, C. Campbell, 1989, British Journal of Cancer.

24-hour cyclophosphamide infusion therapy for malignant mesothelioma of the pleura.

P. Hasleton, N. Thatcher, H. Anderson, 1988, British journal of diseases of the chest.

Effect of temozolomide on central nervous system relapse in patients with advanced melanoma

G. Rustin, N. Thatcher, Y. Summers, 2002, Melanoma research.

The strength of female sex as a prognostic factor in small-cell lung cancer: a pooled analysis of chemotherapy trials from the Manchester Lung Group and Medical Research Council Clinical Trials Unit.

R. Stephens, F. Shepherd, M. Nankivell, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Lack of effect of immunotherapy with BCG and Corynebacterium parvum on hepatic drug hydroxylation in man.

P. Wilkinson, N. Thatcher, G. N. Smith, 1979, British Journal of Cancer.

G. Lyman, N. Thatcher, V. Hanes, 2019, Future oncology.

Urinary-derived monocyte-colony stimulating factor (P-100) following treatment with carboplatin and etoposide in small cell lung cancer (SCLC).

H. Earl, I. Smith, P. Woll, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer.

Nick Thatcher, Shengyan Hong, Jacek Jassem, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Analysis of the glutathione conjugate of paracetamol in human liver microsomal fraction by liquid chromatography mass spectrometry.

N. Thatcher, S. Murray, 2001, Biomedical chromatography : BMC.

A single-blind, randomised, vehicle-controlled dose-finding study of recombinant human granulocyte colony-stimulating factor (lenograstim) in patients undergoing chemotherapy for solid cancers and lymphoma.

A. Howell, D. Cunningham, W. Berdel, 1995, European journal of cancer.

Raltitrexed plus cisplatin is cost-effective compared with pemetrexed plus cisplatin in patients with malignant pleural mesothelioma.

N. Thatcher, B. Woods, D. Scott, 2012, Lung cancer.

Energy balance in patients with advanced NSCLC, metastatic melanoma and metastatic breast cancer receiving chemotherapy – a longitudinal study

A. Howell, N. Thatcher, I. Campbell, 2005, British Journal of Cancer.

9170 Safety and efficacy of first-line bevacizumab (Bv) plus chemotherapy in elderly patients (pts) with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): SAiL (MO19390)

N. Pavlakis, L. Crinò, N. Thatcher, 2009 .

The Value of Erythropoietin Therapy in Cancer Patients

R. Booton, N. Thatcher, 2005 .

Management of chemotherapy-induced anemia in solid tumors.

N. Thatcher, 1998, Seminars in oncology.

Targeting blood vessels for the treatment of non-small cell lung cancer.

J. Tímár, F. Blackhall, N. Thatcher, 2008, Current cancer drug targets.

Necitumumab plus Gemcitabine and Cisplatin as First-Line Therapy in Patients with Stage IV EGFR- Expressing Squamous Non-Small-Cell Lung Cancer: German Subgroup Data from an Open-Label, Randomized Controlled Phase 3 Study (SQUIRE)

C. Kropf-Sanchen, M. Socinski, Michael Thomas, 2016, Oncology Research and Treatment.

Lung cancer after treatment for Hodgkin's lymphoma: a systematic review.

A. Howell, J. Radford, P. Lorigan, 2005, The Lancet. Oncology.

06-Alkylguanine-DNA Alkyltransferase Depletion and Regeneration in Human Peripheral Lymphocytes following Dacarbazine and Fotemustine 1

G. Margison, N. Thatcher, S. Lee, 2006 .

Chemotherapy with vincristine/ifosfamide/carboplatin/etoposide in small cell lung cancer.

P. Lorigan, D. Betticher, N. Thatcher, 1995, Seminars in oncology.

The influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trials.

R. Booton, F. Shepherd, A. Hackshaw, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Annals of Oncology

M. Krzakowski, J. Jassem, E. Tan, 2022 .

The suitability of carboplatin solutions for 14-day continuous infusion by ambulatory pump: an HPLC-dynamic FAB study.

N. Thatcher, M. Dawson, A. McGown, 1993, Journal of pharmaceutical and biomedical analysis.

Seroconversion after influenza vaccination in patients with lung cancer

A. Charlett, N. Thatcher, M. Zambon, 1999, British Journal of Cancer.

A simple outpatient treatment with oral ifosfamide and oral etoposide for patients with small cell lung cancer (SCLC).

N. Thatcher, R. Swindell, M. Lind, 1989, British Journal of Cancer.

The “Hot spleen” phenomenon in metastatic malignant melanoma. Its incidence and relationship with the immune system

D. Crowther, N. Thatcher, K. Phadke, 1982, Cancer.

Achieving survival improvement in thoracic tumours: from therapeutic strategy management to pharmacogenomics.

N. Thatcher, C. Manegold, 2007, Lung Cancer.

Lung cancer after treatment for breast cancer.

A. Howell, C. Faivre-Finn, P. Lorigan, 2010, The Lancet. Oncology.

Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes.

M. Aristides, G. Scagliotti, C. Gridelli, 2005, Lung cancer.

Thoracic radiotherapy for limited-stage small-cell lung cancer: controversies and future developments.

C. Faivre-Finn, P. Lorigan, C. West, 2005, Clinical oncology (Royal College of Radiologists (Great Britain)).

Single fraction prophylactic cranial irradiation for small cell carcinoma of the lung.

N. Thatcher, P. Hopwood, A. Brewster, 1995, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

The impact on the multidisciplinary team of molecular profiling for personalized therapy in non-small cell lung cancer.

R. Booton, K. Kerr, F. Blackhall, 2013, Lung cancer.

Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses.

M. Socinski, F. Shepherd, A. Szczesna, 2015 .

Expression ofepidermal growth factor receptor (EGF-R)innon-small cell lung cancer.Useofarchival tissue andcorrelation ofEGF-Rwith histology, tumoursize, nodestatus andsurvival

P. Hasleton, D. Barnes, N. Thatcher, 1989 .

Chemotherapy for advanced lung cancer.

F. Blackhall, N. Thatcher, 2004, European journal of cancer.

Editorial Comment Chemotherapy for advanced lung cancer

F. Blackhall, N. Thatcher, 2004 .

Origins of hepatomegaly produced by dexamethasone (DEX), pregnenolone 16 alpha-carbonitrile (PCN) and phenobarbitone (PB) in female Sprague-Dawley rats.

N. Thatcher, J. Caldwell, 1994, Biochemical Society transactions.

First- and second-line treatment of advanced metastatic non-small-cell lung cancer: a global view

N. Thatcher, Nicholas Thatcher, 2008, BMC proceedings.

Effects of Corynebacterium parvum on cellular immunity of cancer patients, assayed sequentially over 63 days

D. Crowther, N. Thatcher, R. Swindell, 1981, Cancer.

Effects of BCG and Corynebacterium parvum on immune reactivity in melanoma patients.

D. Crowther, N. Thatcher, 1977, Developments in biological standardization.

Pulmonary carcinoid tumours: a clinico-pathological study of 35 cases.

P. Hasleton, N. Thatcher, V. Blair, 1986, British Journal of Cancer.

Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine–cisplatin plus necitumumab versus gemcitabine–cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer

M. Socinski, R. Kurek, F. Hirsch, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Radiotherapy for small-cell lung cancer-Where are we heading?

C. Faivre-Finn, P. Lorigan, F. Blackhall, 2009, Lung cancer.

Chemotherapy for symptom control in advanced NSCLC

M. Ranson, H. Hansen, N. Thatcher, 1997 .

O6‐methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: Results of a phase II study

A. Arance, G. Margison, N. Thatcher, 2000, International journal of cancer.

Efficacy and Safety of Necitumumab Continuation Therapy in the Phase III SQUIRE Study of Patients With Stage IV Squamous Non–Small‐Cell Lung Cancer

C. Obasaju, M. Socinski, R. Ramlau, 2017, Clinical lung cancer.

Epidermal growth factor receptor immunohistochemistry

F. Hirsch, C. Watkins, P. Bunn, 2008, Cancer.

A randomised study of bolus vs continuous pump infusion of ifosfamide and doxorubicin with oral etoposide for small cell lung cancer.

N. Thatcher, P. Hopwood, H. Anderson, 1993, British Journal of Cancer.

Brampton, M, Stevens MFG. Cancer Research Campaign phase-II trial of temozolomide in malignant melanoma

G. Rustin, N. Bleehen, E. Newlands, 1995 .

Clinical Experience with Gefitinib in Indian Patients

D. Doval, S. Nag, G. Bhattacharyya, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Correction: Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non–small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study

Michael Thomas, N. Thatcher, J. Goldschmidt, 2019, Clinical Cancer Research.

Symptomatic benefit from gemcitabine and other chemotherapy in advanced non-small cell lung cancer: changes in performance status and tumour-related symptoms

M. Ranson, N. Thatcher, H. Anderson, 1995, Anti-cancer drugs.

Cetuximab plus platinum-based chemotherapy as 1st-line treatment in patients with non-small cell lung cancer (NSCLC): a meta-analysis of randomized phase II/III trials

T. Lynch, F. Shepherd, R. Pirker, 2009 .

Escalating drug delivery in cancer chemotherapy: a review of concepts and practice--Part 2.

D. Dodwell, N. Thatcher, H. Gurney, 1993, Annals of Oncology.

Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer.

K. O'Byrne, T. Lynch, F. Shepherd, 2014, Lung cancer.

Anti‐T antibody in malignant melanoma patients. Influence of response and survival following chemotherapy—changes in serum levels following C parvum, BCG immunization

D. Crowther, N. Thatcher, R. Swindell, 1980, Cancer.

Biomarker analysis in a phase III study of pemetrexed-carboplatin versus etoposide-carboplatin in chemonaive patients with extensive-stage small-cell lung cancer.

M. Socinski, G. Scagliotti, E. Smit, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

O-239 Gemcitabine in the treatment of non-small cell lung cancer (NSCLC): A meta-analysis of survival and progression free survival data

G. Scagliotti, J. Vansteenkiste, J. Schiller, 2003 .

87 Effects of prophylactic cranial irradiation (PCI) in small cell lung cancer (SCLC); results of UKCCCR/EORTC randomised trial

R. Stephens, A. Gregor, A. Cull, 1995 .

Novel approaches with ifosfamide in small cell lung cancer.

N. Thatcher, M. Lind, T. Cerny, 1992, Seminars in Oncology.

A phase I study of rDNA alpha-2b interferon as a 6-week continuous intravenous infusion

David C. Smith, N. Thatcher, J. Wagstaff, 2004, Cancer Chemotherapy and Pharmacology.

The Effect of Necitumumab in Combination with Gemcitabine plus Cisplatin on Tolerability and on Quality of Life: Results from the Phase 3 SQUIRE Trial

C. Schumann, C. Obasaju, M. Socinski, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Early Stage Lung Cancer—New Approaches to Evaluation and Treatment: Conference Summary Statement

C. Henschke, J. Jett, G. Scagliotti, 2005, Clinical Cancer Research.

Not breathing easier.

N. Thatcher, V. Blair, S. Gomm, 1998, Environmental health perspectives.

Increasing the dose intensity of chemotherapy by means of granulocyte-colony stimulating factor (G-CSF) support in the treatment of small cell lung cancer (SCLC)

R. Stephens, D. Girling, P. Clark, 1996, European journal of cancer.

Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: treatment rationale and protocol dynamics of the AvaALL (M

A. Rossi, C. Gridelli, C. Langer, 2011, Clinical lung cancer.

Bioavailability of ifosfamide in patients with bronchial carcinoma

P. Wilkinson, N. Thatcher, J. Margison, 2004, Cancer Chemotherapy and Pharmacology.

A comparison between a single agent short course chemotherapy regimen and a quadruple prolonged course regimen for small-cell bronchogenic carcinoma of limited extent.

N. Thatcher, D. Brown, K. Carroll, 1983, British journal of diseases of the chest.

Dacarbazine and interferon‐α 2a in advanced malignant melanoma: high response rate and prolongation of response duration occur in different patient subpopulations

D. Betticher, N. Thatcher, C. Morris, 1995, Melanoma research.

P-569 The relationship between treatment-free interval (TFI) and outcomes to therapy in patients with relapsed Small Cell Lung Cancer (SCLC): A review of 631 patients treated with IV topotecan in 6 studies

A. Ardizzoni, N. Thatcher, G. Ross, 2003 .

A phase I toxicity study of human rDNA interferon in patients with solid tumours

A. Howell, D. Crowther, N. Thatcher, 2004, Cancer Chemotherapy and Pharmacology.

Randomised phase III trial of docetaxel/carboplatin vs MIC/MVP chemotherapy in advanced non-small cell lung cancer (NSCLC) - final results of a British Thoracic Oncology Group (BTOG) trial.

R. Booton, K. O'Byrne, C. Faivre-Finn, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patient selection and predicting response to recombinant human erythropoietin in anemic cancer patients.

N. Thatcher, D. Henry, 1996, Seminars in hematology.

Haematopoietic growthfactors andlungcancer treatment

N. Thatcher, 1992 .

A phase II study of carboplatin and vinorelbine in patients with poor prognosis small cell lung cancer.

H. Mackay, I. Smith, N. Thatcher, 2003, Clinical oncology (Royal College of Radiologists (Great Britain)).

CHEMOTHERAPY (CT) PLUS CETUXIMAB AS 1ST-LINE TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): META-ANALYSIS OF INDIVIDUAL PATIENT DATA

T. Lynch, F. Shepherd, R. Pirker, 2010 .

9168 Safety and efficacy of first-line bevacizumab-based therapy in advanced non-small cell lung cancer (NSCLC): results of the SAiL study (MO19390)

N. Pavlakis, Yi-long Wu, L. Crinò, 2009 .

Recombinant interleukin-2 and other types of treatment of advanced malignant melanoma.

N. Thatcher, 1991, Current Opinion in Oncology.

Glutathione-S-Transferase P1 Isoenzyme Polymorphisms, Platinum-Based Chemotherapy, and Non-small Cell Lung Cancer

T. Ward, Julie Morris, J. Heighway, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phase II/III randomized study in advanced non-small cell lung cancer (NSCLC) with first line combination versus sequential gemcitabine (G) and docetaxel (D): Update on quality of life (QoL), toxicity, and costs

C. Kortsik, N. Thatcher, L. Pilz, 2005 .

Changes in nonspecific lymphoid (NK, K, T cell) cytotoxicity following BCG immunisation of healthy subjects

D. Crowther, N. Thatcher, 2004, Cancer Immunology and Immunotherapy.

B2-06: A pragmatic, randomised study to compare the hospitalisation rates of two platinum-based outpatient regimens (Gemicitabine/Cisplatin vs. Gemcitabine/Carboplatin) in non-small cell lung cancer (NSCLC) - UK Swiss collaboration

C. Faivre-Finn, F. Blackhall, N. Thatcher, 2007 .

Three months' treatment with cyclophosphamide, VP‐16‐213 followed by methotrexate and thoracic radiotherapy for small cell lung cancer

R. James, P. Barber, N. Thatcher, 1985, Cancer.

Lung volume reduction surgery for severe emphysema increases exercise capacity but not does not affect mortality

R. Booton, N. Thatcher, M. Jones, 2003, Thorax.

Pharmacokinetics of high-dose cyclophosphamide in patients with metastatic bronchogenic carcinoma

S. B. Lucas, P. Wilkinson, N. Thatcher, 2004, Cancer Chemotherapy and Pharmacology.

P-574 Randomised phase 3 trial of autologous blood progenitor cell and filgrastim supported dose dense ICE chemotherapy versus standard ICE in good prognosis small cell lung cancer (SCLC) — a different toxicity profile

P. Lorigan, P. Woll, N. Thatcher, 2003 .

O-275 Ifosfamide, carboplatin and etoposide with mid-cycle vincristine (ICE-V) versus standard chemotherapy (C) in patients with small cell lung cancer (SCLC) and good performance status (PS): results of an MRC randomized trial (LU21)

D. Girling, N. Thatcher, W. Qian, 2003 .

Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients.

J. Verweij, J. von Pawel, U. Gatzemeier, 1998, Journal of Clinical Oncology.

Immunoscintigraphy with 99mTc labelled F(ab′)2 fragments of an anti melanoma monoclonal antibody (225.28S) in patients with metastatic malignant melanoma

N. Thatcher, S. Owens, T. Cerny, 2004, European Journal of Nuclear Medicine.

Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer.

C. Watkins, P. Bunn, W. Franklin, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

C. Schumann, M. Socinski, R. Kurek, 2015, The Lancet. Oncology.

Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment

Edward S. Kim, C. Obasaju, M. Socinski, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Therapeutic vaccines for cancer: an overview of clinical trials

I. Melero, H. Mellstedt, N. Thatcher, 2014, Nature Reviews Clinical Oncology.

1st ESMO Consensus Conference in lung cancer; Lugano 2010: small-cell lung cancer.

P. Postmus, R. Stahel, E. Felip, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

G- and GM-CSF.

N. Thatcher, M. Middleton, 1998, International journal of antimicrobial agents.

Sequential administration of dacarbazine and fotemustine in disseminated melanoma

S Aamdal, SM Lee, JA Radford, 1991 .

Sequential DTIC and fotemustine in the treatment of metastatic melanoma.

Sm Lee, Sl Shelbourn, N Thatcher, 1991 .